A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Tolvaptan (Primary)
- Indications Ascites; Oedema
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 03 Mar 2021 Results published in the Japanese Journal of Clinical Oncology
- 08 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.